Hereditary angioedema (HAE) is one of the most commercially valuable rare disease markets in medicine, yet for the people who live with it, treating an attack has often meant a needle or an infusion at the worst possible moment. That is the problem Pharvaris is trying to solve with a capsule.
On October 8, 2026, The Lancet published the pivotal Phase 3 RAPIDe-3 results for deucrictibant, an investigational oral bradykinin B2 receptor antagonist. A single 20 mg immediate-release capsule produced onset of symptom relief in a median of 1.28 hours, compared with more than 12 hours on placebo (p < 0.0001). The FDA has accepted the New Drug Application and set a PDUFA target action date of April 23, 2027. Deucrictibant is not yet approved.
In This Deep Dive:
- Why this matters now: injection hesitation and delayed treatment in acute HAE attacks.
- What actually happened: the RAPIDe-3 crossover trial and its primary and secondary endpoints.
- The obvious read versus the deeper signal: convenience versus earlier treatment of every attack.
- Competitive taxonomy: on-demand and preventive HAE therapies by mechanism and route.
- The Evidence Ladder: from receptor chemistry to Phase 3 publication.
- Illustrative health economics and the HealthTech Investor's Signal.
- Counter-thesis and four indicators to watch over the next 12 to 24 months.
Why this matters now
HAE is a rare genetic condition, estimated at roughly 1 in 50,000 people, in which uncontrolled bradykinin signaling causes unpredictable swelling of the skin, abdomen or airway. Preventive therapies have improved substantially, but many patients still experience breakthrough attacks that need on-demand treatment.
Current on-demand options are mostly injected or infused: subcutaneous icatibant, intravenous C1 esterase inhibitors, and clinic-administered ecallantide. Treatment guidelines recommend treating attacks as early as possible, but injection pain, preparation time and portability can push people to wait. An oral option changes the moment of decision. It is also worth noting that the oral era has already begun: KalVista's sebetralstat, an oral plasma kallikrein inhibitor, was approved for on-demand use in 2025. Deucrictibant would be the first oral option to block the B2 receptor itself.
What actually happened
RAPIDe-3 (NCT06343779) was a randomized, double-blind, placebo-controlled crossover study run across 59 sites in 24 countries. According to the company and the published paper, 134 patients with HAE type 1 or type 2 were randomized, and 88 paired attacks were treated with either deucrictibant 20 mg or placebo.
The primary endpoint, time to onset of symptom relief, favored deucrictibant with a median of 1.28 hours versus more than 12 hours for placebo (hazard ratio 4.85). The drug met all 11 key secondary endpoints, including a median time to complete symptom resolution of 11.95 hours, and the company reports that 87% of attacks were treated with a single dose. Pharvaris describes the drug as well tolerated, with no treatment-related serious adverse events reported in the study.
The obvious read versus the deeper signal
The obvious read is convenience: a pill instead of a needle. That matters, but it undersells the clinical idea.
The deeper signal is timing. If treatment is easy to carry and easy to take, patients may treat at the first sign of an attack rather than waiting until swelling is severe enough to justify an injection. Earlier treatment is the core principle of HAE attack management, and a delivery format that removes friction is a direct way to act on it. Whether that translates into shorter attacks and fewer emergency visits in everyday use is exactly what post-approval data will need to show.
